| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Johnson & Johnson's strong product and service development capabilities are showcased through its strategic business reorganization, particularly the planned spin-off of its orthopedics unit to intensify focus on core areas like MedTech. The company is also advancing its drug pipeline and product innovations, underscoring its commitment to growth and market demands. However, product performance, as indicated by the stabilization of Stelara's erosion, reveals potential weaknesses that could impact revenue streams if innovation doesn't keep pace. Overall, J&J is positioned for long-term success with a robust pipeline and strategic initiatives, despite facing certain performance challenges. |
| The price action of JOHNSON & JOHNSON (JNJ) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.3 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for JNJ since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.5, and the negative at -0.2 on 2025-10-17. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (2.8) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| JNJ | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-17 | 0%(0.1%) | 0 | 0% | 0.3 | 2.8 | -1 | |||||||
| 2025-10-16 | 0%(0.1%) | 0 | 0% | 0.3 | 2.7 | -1 | |||||||
| 2025-10-15 | 0%(0.1%) | 0 | 0% | 0.3 | 3 | 6 | |||||||
| 2025-10-14 | 1%(0.1%) | 0 | 0% | 0.3 | 2.9 | 5.3 | |||||||
| 2025-10-13 | 0%(0%) | 0 | 0% | -0.1 | 0.6 | -1 | |||||||
| 2025-10-12 | 0%(0%) | 0 | 0% | -0.1 | 0.7 | -1 | |||||||
| 2025-10-11 | 0%(0%) | 0 | 0% | -0.1 | 0.2 | -1 | |||||||
| 2025-10-10 | 0%(0%) | 0 | 0% | -0 | 0.9 | 5 | |||||||
| 2025-10-09 | 0%(0%) | 0 | 0% | 0.1 | 1.3 | -1 | |||||||
| 2025-10-08 | 0%(0%) | 0 | 0% | 0 | 1.2 | 7 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-10-17 17:02:38 The anticipated loss of exclusivity for Stelara poses challenges, but the overall outlook remains optimistic. |
| 2025-10-17 17:02:38 The expanding drug pipeline suggests Johnson & Johnson's commitment to innovation and future growth. |
| 2025-10-17 17:02:38 The recent stock gain reflects investor confidence in Johnson & Johnson's financial health. |
| 2025-10-17 17:02:38 The upbeat sales outlook for J&J indicates positive growth potentials ahead. |
| 2025-10-17 17:02:38 Johnson & Johnson's strong Q3 results demonstrate its ability to perform well in a challenging market environment. |